---

$30.08

-0.8320 ( -2.69% ) 45.2K

MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and anticipate reporting topline data in the third quarter of 2025.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-09-17	Buy	1023103.00	New Enterprise Associates 17, L.P.
2024-09-17	Buy	3927774.00	Frazier Life Sciences X, L.P.
2024-09-17	Buy	1386335.00	Aynechi Tiba
2024-09-17	Buy	2658428.00	GORDON CARL L
2024-09-17	Buy	1023103.00	Florence Anthony A. Jr.
2024-09-17	Buy	1023103.00	Makhzoumi Mohamad
2024-09-17	Buy	1023103.00	Walker Paul Edward
2024-09-17	Buy	1023103.00	Yang Rick
2024-09-17	Buy	3927774.00	Heron Patrick J